US2022267366A1PendingUtilityA1

Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment

79
Assignee: ATEA PHARMACEUTICALS INCPriority: Mar 6, 2015Filed: May 3, 2021Published: Aug 25, 2022
Est. expiryMar 6, 2035(~8.7 yrs left)· nominal 20-yr term from priority
Inventors:Jean-Pierre SommadossiAdel Moussa
A61K 31/7076A61P 31/14C07H 19/20C07H 19/207C07H 19/16
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A compound of the structure:or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising an effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof and an effective amount of an additional anti-viral compound selected from a protease inhibitor, a NS5B polymerase inhibitor, and a NS5A inhibitor in a pharmaceutically acceptable carrier. 
       
     
     
         2 . The pharmaceutical composition of  claim 1  comprising a compound of the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         3 . The pharmaceutical composition of  claim 1  comprising a compound of the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the additional anti-viral compound is a protease inhibitor. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the protease inhibitor is a NS3/4A protease inhibitor. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the additional anti-viral compound is a NS5A inhibitor. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the additional anti-viral compound is a NS5B polymerase inhibitor. 
     
     
         8 . The pharmaceutical composition of  claim 1 , in an oral dosage form. 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the oral dosage form is a solid dosage form. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the solid dosage form is a tablet or capsule. 
     
     
         11 . The pharmaceutical composition of  claim 8 , wherein the oral dosage form is a liquid dosage form. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the liquid dosage form is a suspension or solution. 
     
     
         13 . The pharmaceutical composition of  claim 1 , in an intravenous formulation. 
     
     
         14 . The pharmaceutical composition of  claim 1 , in a parenteral formulation. 
     
     
         15 . The pharmaceutical composition of  claim 2 , wherein the additional anti-viral compound is a protease inhibitor. 
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein the protease inhibitor is a NS3/4A protease inhibitor. 
     
     
         17 . The pharmaceutical composition of  claim 2 , wherein the additional anti-viral compound is a NS5A inhibitor. 
     
     
         18 . The pharmaceutical composition of  claim 2 , wherein the additional anti-viral compound is a NS5B polymerase inhibitor. 
     
     
         19 . The pharmaceutical composition of  claim 2 , in an oral dosage form. 
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the oral dosage form is a solid dosage form. 
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein the solid dosage form is a tablet or capsule. 
     
     
         22 . The pharmaceutical composition of  claim 19 , wherein the oral dosage form is a liquid dosage form. 
     
     
         23 . The pharmaceutical composition of  claim 22 , wherein the liquid dosage form is a suspension or solution. 
     
     
         24 . The pharmaceutical composition of  claim 2 , in an intravenous formulation. 
     
     
         25 . The pharmaceutical composition of  claim 2 , in a parenteral formulation. 
     
     
         26 . The pharmaceutical composition of  claim 3 , wherein the additional anti-viral compound is a protease inhibitor. 
     
     
         27 . The pharmaceutical composition of  claim 26 , wherein the protease inhibitor is a NS3/4A protease inhibitor. 
     
     
         28 . The pharmaceutical composition of  claim 3 , wherein the additional anti-viral compound is a NS5A inhibitor. 
     
     
         29 . The pharmaceutical composition of  claim 3 , wherein the additional anti-viral compound is a NS5B polymerase inhibitor. 
     
     
         30 . The pharmaceutical composition of  claim 3 , in an oral dosage form. 
     
     
         31 . The pharmaceutical composition of  claim 30 , wherein the oral dosage form is a solid dosage form. 
     
     
         32 . The pharmaceutical composition of  claim 31 , wherein the solid dosage form is a tablet or capsule. 
     
     
         33 . The pharmaceutical composition of  claim 30 , wherein the oral dosage form is a liquid dosage form. 
     
     
         34 . The pharmaceutical composition of  claim 33 , wherein the liquid dosage form is a suspension or solution. 
     
     
         35 . The pharmaceutical composition of  claim 3 , in an intravenous formulation. 
     
     
         36 . The pharmaceutical composition of  claim 3 , in a parenteral formulation.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.